SAN MATEO, Calif., May 11, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, May 15, 2012 at 9:00AM PDT, to discuss first quarter 2012 financial results and provide a business update.
Conference call details:
| Date: | Tuesday, May 15, 2012 |
| Time: | 12:00pm EDT, 9:00am PDT |
| Dial-in (U.S. and Canada): | (877) 681 – 1326 |
| Dial-in (International): | (708) 290 – 1158 |
| Web cast: | www.talontx.com |
An archived version of the webcast will also be available via the company's website following the call.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon's lead product candidate Marqibo® is seeking accelerated approval for Philadelphia chromosome (Ph) negative advanced relapsed/refractory acute lymphoblastic leukemia. The PDUFA date is August 12, 2012.
In addition to Marqibo, the Company has additional pipeline opportunities some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
The Talon Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290